New Drug for Management of Severe Uncontrolled Asthma: Tezepelumab

2022 GINA Main Report - Global Initiative for Asthma - GINA. 2022. Available from: https://ginasthma.org/gina-reports/

Dorey-Stein, Z.L.; Shenoy, K.V. Tezepelumab as an merging therapeutic option for the treatment of severe asthma: Evidence to ate. Drug Des. Devel. Ther., 2021, 15, 331-338.
[http://dx.doi.org/10.2147/DDDT.S250825] [PMID: 33536746]

Menzies-Gow, A.; Wechsler, M.E.; Brightling, C.E. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir. Res., 2020, 21(1), 268.
[http://dx.doi.org/10.1186/s12931-020-01505-x] [PMID: 33059715]

Meteran, H.; Tønnesen, L.L.; Sivapalan, P.; Ingebrigtsen, T.S.; Jensen, J.U.S. Recent developments in the management of severe asthma. Breathe, 2022, 18(1), 210178.
[http://dx.doi.org/10.1183/20734735.0178-2021] [PMID: 36338257]

Menzies-Gow, A.; Steenkamp, J.; Singh, S.; Erhardt, W.; Rowell, J.; Rane, P.; Martin, N.; Llanos, J.P.; Quinton, A. Tezepelumab compared with other biologics for the treatment of severe asthma: A systematic review and indirect treatment comparison. J. Med. Econ., 2022, 25(1), 679-690.
[http://dx.doi.org/10.1080/13696998.2022.2074195] [PMID: 35570578]

Matera, M.G.; Rogliani, P.; Calzetta, L.; Cazzola, M. Inhibitors for asthma: Current status and future prospects. Drugs, 2020, 80(5), 449, 458.

McGregor, M.C.; Krings, J.G.; Nair, P.; Castro, M. Role of biologics in asthma. Am. J. Respir. Crit. Care Med., 2019, 199(4), 433-445.
[http://dx.doi.org/10.1164/rccm.201810-1944CI] [PMID: 30525902]

Calhoun, W.J.; Chupp, G.L. The new era of add-on asthma treatments: Where do we stand? Allergy Asthma Clin. Immunol., 2022, 18(1), 42.
[http://dx.doi.org/10.1186/s13223-022-00676-0] [PMID: 35598022]

Cheng, S.L. Molecular targets for biological therapies of severe asthma: Focus on benralizumab and tezepelumab. Life, 2021, 11(8), 744.
[http://dx.doi.org/10.3390/life11080744] [PMID: 34440488]

Perikleous, E.P.; Steiropoulos, P.; Nena, E.; Paraskakis, E. Biologic therapies in pediatric asthma. J. Pers. Med., 2022, 12(6), 999.
[http://dx.doi.org/10.3390/jpm12060999]

Ando, K.; Fukuda, Y.; Tanaka, A.; Sagara, H. Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: A systematic review and network meta-analysis. Cells, 2022, 11(5), 819.
[http://dx.doi.org/10.3390/cells11050819] [PMID: 35269440]

Mathur, S.; Hill, J.; Ambrose, C.; Martin, N.; Llanos-Ackert, J.P.; Martin, N.; Colice, G. Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype. J. Allergy Clin. Immunol., 2023, 151(2), AB17.
[http://dx.doi.org/10.1016/j.jaci.2022.12.057]

Adam, D.N.; Gooderham, M.J.; Beecker, J.R.; Hong, C.H.; Jack, C.S.; Jain, V. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol., 2023, 37(6), 1135-1148.

Tezspire (tezepelumab) approved in the US for severe asthma. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html

Menzies-Gow, A.; Corren, J.; Bourdin, A.; Chupp, G.; Israel, E.; Wechsler, M.E.; Brightling, C.E.; Griffiths, J.M.; Hellqvist, Å.; Bowen, K.; Kaur, P.; Almqvist, G.; Ponnarambil, S.; Colice, G. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med., 2021, 384(19), 1800-1809.
[http://dx.doi.org/10.1056/NEJMoa2034975] [PMID: 33979488]

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype. Available from: https://www.amgen.com/newsroom/press-releases/2018/09/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-severe-asthma-without-an-eosinophilic-phenotype

Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html

Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma. Available from: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-recommended-for-approval-in-the-eu-by-chmp.html

Tezspire approved in the EU for the treatment of severe asthma. Available from: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma.html

Tezspire approved in Japan for the treatment of severe asthma. Available from: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html

Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma. Available from: https://www.astrazeneca.com/media-centre/press-releases/2017/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma-06092017.html#

Marone, G.; Spadaro, G.; Braile, M.; Poto, R.; Criscuolo, G.; Pahima, H.; Loffredo, S.; Levi-Schaffer, F.; Varricchi, G. Tezepelumab: A novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin. Investig. Drugs, 2019, 28(11), 931-940.
[http://dx.doi.org/10.1080/13543784.2019.1672657] [PMID: 31549891]

Bel, E.H. Moving upstream — Anti-TSLP in persistent uncontrolled asthma. N. Engl. J. Med., 2017, 377(10), 989-991.
[http://dx.doi.org/10.1056/NEJMe1709519] [PMID: 28877024]

Corren, J.; Ambrose, C.S.; Sałapa, K.; Roseti, S.L.; Griffiths, J.M.; Parnes, J.R.; Colice, G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J. Allergy Clin. Immunol. Pract., 2021, 9(12), 4334-4342.e6.
[http://dx.doi.org/10.1016/j.jaip.2021.07.045] [PMID: 34358701]

Ly, N.; Zheng, Y.; Griffiths, J.M.; van der Merwe, R.; Agoram, B.; Parnes, J.R.; Roskos, L. Pharmacokinetic and pharmacodynamic modeling of tezepelumab to guide phase 3 dose selection for patients with severe asthma. J. Clin. Pharmacol., 2021, 61(7), 901-912.
[http://dx.doi.org/10.1002/jcph.1803] [PMID: 33368307]

Matucci, A.; Micheletto, C.; Vultaggio, A. Severe asthma and biologics: Managing complex patients. J. Investig. Allergol. Clin. Immunol., 2023, 33(3), 168-178.
[http://dx.doi.org/10.18176/jiaci.0856] [PMID: 36059229]

Feist, J.; Lipari, M.; Kale-Pradhan, P. Tezepelumabin the treatment of uncontrolled severe asthma. Ann Pharmacother., 2022, 57(1), 62-70.

Hoy, S.M. Tezepelumab: First approval. Drugs, 2022, 82(4), 461-468.
[http://dx.doi.org/10.1007/s40265-022-01679-2] [PMID: 35184265]

MedWatch: The FDA safety information and adverse event reporting program. Available from: www.fda.gov/medwatch

Parnes, J.; Molfino, N.A.; Colice, G.; Martin, U.; Corren, J.; Menzies-Gow, A. Targeting TSLP in Asthma. J. Asthma Allergy, 2022, 15, 749-765.
[http://dx.doi.org/10.2147/JAA.S275039] [PMID: 35685846]

Menzies-Gow, A.; Colice, G.; Griffiths, J.M.; Almqvist, G.; Ponnarambil, S.; Kaur, P.; Ruberto, G.; Bowen, K.; Hellqvist, Å.; Mo, M.; Garcia Gil, E. NAVIGATOR: A phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir. Res., 2020, 21(1), 266.
[http://dx.doi.org/10.1186/s12931-020-01526-6] [PMID: 33050934]

Menzies-Gow, A.; Bourdin, A.; Chupp, G.; Israel, E.; Hellqvist, Å.; Hunter, G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study. Ann Allergy Asthma Immunol, 2023, 131(3), 343-348.e2.

Corren, J.; Menzies-Gow, A.; Chupp, G.; Israel, E.; Korn, S.; Cook, B.; Ambrose, C.S.; Hellqvist, Å.; Roseti, S.L.; Molfino, N.A.; Llanos, J.P.; Martin, N.; Bowen, K.; Griffiths, J.M.; Parnes, J.R.; Colice, G. Efficacy of tezepelumab in severe, uncontrolled asthma: Pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am. J. Respir. Crit. Care Med., 2023, 208(1), 13-24.
[http://dx.doi.org/10.1164/rccm.202210-2005OC] [PMID: 37015033]

Wechsler, M.E.; Colice, G.; Griffiths, J.M.; Almqvist, G.; Skärby, T.; Piechowiak, T.; Kaur, P.; Bowen, K.; Hellqvist, Å.; Mo, M.; Garcia Gil, E. SOURCE: A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir. Res., 2020, 21(1), 264.
[http://dx.doi.org/10.1186/s12931-020-01503-z] [PMID: 33050928]

Menzies-Gow, A.; Wechsler, M.E.; Brightling, C.E.; Korn, S.; Corren, J.; Israel, E.; Chupp, G.; Bednarczyk, A.; Ponnarambil, S.; Caveney, S.; Almqvist, G.; Gołąbek, M.; Simonsson, L.; Lawson, K.; Bowen, K.; Colice, G.; Hetzel, J.L.; Fiterman, J.; Souza Machado, A.; Antila, M.A.; Lima, M.A.; Minamoto, S.E.T.; Blanco, D.C.; Bezerra, P.G.M.; Houle, P-A.; Lemiere, C.; Melenka, L.S.; Leigh, R.; Mitchell, P.; Anees, S.; Pek, B.; Chouinard, G.; Cheema, A.S.; Yang, W.H-C.; Philteos, G.; Chanez, P.; Bourdin, A.; Devouassoux, G.; Taille, C.; De Blay, F.; Leroyer, C.; Beurnier, A.; Garcia, G.; Girodet, P-O.; Blanc, F-X.; Magnan, A.; Wanin, S.; Just, J.; Linde, R.; Zielen, S.; Förster, K.; Geßner, C.; Jandl, M.; Buhl, R.O.; Korn, S.; Kornmann, M.O.; Linnhoff, A.; Ludwig-Sengpiel, A.; Ehlers, M.; Schmoller, T.; Steffen, H.; Hoffmann, M.; Kirschner, J.; Schmidt, O.; Welte, T.; Temme, H.; Wand, O.; Bar-Shai, A.; Izbicki, G.; Berkman, N.; Fink, G.; Shitrit, D.; Adir, Y.; Kuna, P.; Rewerska, B.; Pisarczyk-Bogacka, E.; Kurbacheva, O.; Mikhailov, S.L.; Vasilev, M.; Emelyanov, A.; Wali, S.; Albanna, A.; van Zyl-Smit, R.; Abdullah, I.; Abdullah, I.; Bernhardi, D.; Hoosen, F.; Irusen, E.; Kalla, I.; Lakha, D.; Mitha, E.; Naidoo, V.; Nell, H.; Padayachee, T.; Reddy, J.; Petrick, F.; van der Walt, E.; Vawda, Z.F.A.; Park, H-S.; Lee, S.H.; Kim, M-K.; Park, J-W.; Cho, Y.S.; Lee, B.J.; Chang, Y-S.; Park, C-S.; Lee, K.H.; Lee, S.Y.; Yoon, H.K.; Sohn, K.H.; Park, M.J.; Min, K.H.; Cho, Y.J.; Park, H.K.; Lee, Y.C.; Lee, J.; Sheu, C-C.; Tu, C-Y.; Lee, K-Y.; Bavbek, S.; Gemicioglu, B.; Ediger, D.; Kalkan, I.K.; Makieieva, N.; Ostrovskyy, M.; Dytyatkovs’ka, Y.; Mostovoy, Y.M.; Lebed, K.; Yakovenko, O.; Adams, A.; Mooring, T.; Torres, L., Jr; Sexton, M.; Thompson, E.; Bernstein, J.A.; Lisi, P.; Chappel, C.M.; Cole, J.; Greenwald, G.I.; Jones, C.; Klein, R.M.; Pham, D.N.; Spangenthal, S.; Weinstein, S.F.; Windom, H.H.; Kao, N.L.; Leong, M.A.; Mehta, V.; Moore, W.C.; Bhat, S.; Aish, B.; Meltzer, S.M.; Corren, J.; Moss, M.H.; Kerwin, E.M.; Delgado, J.P.; Lucksinger, G.H.; Thompson, C.A.; Chupp, G.; Alpizar, S.A.; Vadgama, S.V.; Zafar, Z.; Jacobs, J.S.; Lugogo, N.J.; Jain, N.; Sher, L.D.; Andrawis, N.S.; Fuentes, D.; Boren, E.J.; Gonzalez, E.G.; Talreja, N.; Durrani, S.S.; Israel, E.; Sekhsaria, S.; DeLeon, S.; Shukla, M.; Totszollosy Tarpay, M.M.; Fakih, F.; Hudes, G.; Tillinghast, J.P.; Korenblat, P.E.; Shenoy, K.; Que, L.; Kureishy, S.A.; Umeh, F.C.; Nguyen, V.N.; Chu, H.T.; Nguyen, T.T.D. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): A randomised, placebo-controlled extension study. Lancet Respir. Med., 2023, 11(5), 425-438.
[http://dx.doi.org/10.1016/S2213-2600(22)00492-1] [PMID: 36702146]

Kurihara, M.; Kabata, H.; Irie, M.; Fukunaga, K. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma. Allergol. Int., 2023, 72(1), 24-30.
[http://dx.doi.org/10.1016/j.alit.2022.11.006] [PMID: 36470789]

Shinkai, M.; Ebisawa, M.; Fukushima, Y.; Takeuchi, S.; Okada, H.; Tokiyo, T.; Hayashi, N.; Takikawa, M.; Colice, G.; Almqvist, G. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: Results of the NOZOMI study. J. Asthma, 2023, 60(3), 616-624.
[http://dx.doi.org/10.1080/02770903.2022.2082309] [PMID: 35707873]

Corren, J.; Ambrose, C.S.; Griffiths, J.M.; Hellqvist, Å.; Lindsley, A.W.; Llanos, J.P.; Colice, G.; Menzies-Gow, A. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study. Clin. Exp. Allergy, 2023, 53(4), 417-428.
[http://dx.doi.org/10.1111/cea.14256] [PMID: 36507576]

Wechsler, M.E.; Menzies-Gow, A.; Brightling, C.E.; Kuna, P.; Korn, S.; Welte, T.; Griffiths, J.M.; Sałapa, K.; Hellqvist, Å.; Almqvist, G.; Lal, H.; Kaur, P.; Skärby, T.; Colice, G.; Cambursano, V.H.; Fernandez, M.J.; Scherbovsky, F.D.; Yanez, A.; Tolcachier, A.J.; Stok, A.M.; Verra, F.J.B.; Korn, S.; Forster, K.; Rolke, M.; Ludwig-Sengpiel, A.; Schmoller, T.; Schmidt, O.; Milger-Kneidinger, K.; Hoffmann, M.; Temme, H.; Linnhoff, A.; Welte, T.; Kirschner, J.; Kuna, P.; Rewerska, B.; Pisarczyk-Bogacka, E.; Haak Lee, S.; Jae Lee, B.; Park, H-W.; Park, J-W.; Young Lee, S.; Sook Cho, Y.; Ho Lee, K.; Bavbek, S.; Gemicioglu, B.; Ediger, D.; Koca Kalkan, I.; Hanta, I.; Yorgancioglu, A.; DytyatkovsKa, Y.; Mostovoy, Y.M.; Lebed, K.; Yakovenko, O.; Bernstein, D.I.; Tillinghast, J.P.; Que, L.; Madison, J.; Rambasek, T.; Shenoy, K.; Thompson, C.A.; Chappel, C.M.; Hudes, G.; Sorial, E.; Kureishy, S.A.; Rehman, S.M.; Lugogo, N.; Gonzalez, E.G.; Umeh, F.C.; Boren, E.J.; Sigmon, J.; Ismail, H.; Mohan, A.; Bansal, S.; Kaelin, T.D. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): A randomised, placebo-controlled, phase 3 study. Lancet Respir. Med., 2022, 10(7), 650-660.
[http://dx.doi.org/10.1016/S2213-2600(21)00537-3] [PMID: 35364018]

Menzies-Gow, A.; Ponnarambil, S.; Downie, J.; Bowen, K.; Hellqvist, Å.; Colice, G. DESTINATION: A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir. Res., 2020, 21(1), 279.
[http://dx.doi.org/10.1186/s12931-020-01541-7] [PMID: 33087119]

Murrison, L.B.; Ren, X.; Preusse, K.; He, H.; Kroner, J.; Chen, X.; Jenkins, S.; Johansson, E.; Biagini, J.M.; Weirauch, M.T.; Kopan, R.; Martin, L.J.; Khurana, H.G.K. TSLP disease-associated genetic variants combined with airway TSLP expression influence asthma risk. J. Allergy Clin. Immunol., 2022, 149(1), 79-88.
[http://dx.doi.org/10.1016/j.jaci.2021.05.033] [PMID: 34111451]

Varricchi, G.; Pecoraro, A.; Marone, G.; Criscuolo, G.; Spadaro, G.; Genovese, A.; Marone, G. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front. Immunol., 2018, 9(JUL), 1595.
[http://dx.doi.org/10.3389/fimmu.2018.01595] [PMID: 30057581]

Modena, BD; Doroudchi, A; Patel, P; Sathish, V Leveraging genomics to uncover the genetic, environmental and age-related factors leading to asthma. In: Genomic and Precision Medicine: Infectious and Inflammatory Disease; , 2019; 1, pp. 331-381.
[http://dx.doi.org/10.1016/B978-0-12-801496-7.00018-6]

West, E.E.; Kashyap, M.; Leonard, W.J. TSLP: A key regulator of asthma pathogenesis. Drug Discov. Today Dis. Mech., 2012, 9(3-4), e83-e88.
[http://dx.doi.org/10.1016/j.ddmec.2012.09.003] [PMID: 24348685]

Plaza, V.; Cañete, C.; Domingo, C.; Martínez, R.C.; Muñoz, X. Efficacy and potential positioning of tezepelumab in the treatment of severe asthma. Open Respiratory Archives, 2023, 5(2), 100231.
[http://dx.doi.org/10.1016/j.opresp.2022.100231] [PMID: 37496871]

Marković, I.; Savvides, S.N. Modulation of signaling mediated by tslp and il-7 in inflammation, autoimmune diseases, and cancer. Front. Immunol., 2020, 11, 1557.
[http://dx.doi.org/10.3389/fimmu.2020.01557] [PMID: 32849527]

Pelaia, C.; Pelaia, G.; Crimi, C.; Maglio, A.; Gallelli, L.; Terracciano, R.; Vatrella, A. Tezepelumab: A potential new biological therapy for severe refractory asthma. Int. J. Mol. Sci., 2021, 22(9), 4369.
[http://dx.doi.org/10.3390/ijms22094369] [PMID: 33922072]

Matera, M.G.; Ora, J.; Rogliani, P.; Cazzola, M. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. Expert Opin. Drug Discov., 2023, 18(9), 951-963.
[http://dx.doi.org/10.1080/17460441.2023.2230885] [PMID: 37387523]

Dorey-Stein, Z.L.; Shenoy, K.V. Tezepelumab as an emerging therapeutic option for the treatment of severe asthma: evidence to date. Drug Des. Devel. Ther., 2021, 15, 331-338.
[http://dx.doi.org/10.2147/DDDT.S250825] [PMID: 33536746]

Kogut, S.J.; Campbell, J.D.; Pearson, S.D. The influence of US drug price dynamics on cost-effectiveness analyses of biologics. Value Health, 2023, 26(3), 378-383.
[http://dx.doi.org/10.1016/j.jval.2022.12.010] [PMID: 36566884]

Habash, M.; Guiang, H.; Mayers, I.; Quinton, A.; Vuong, V.; Dineen, A.; Singh, S.; Gibson, D.; Turner, A.P. Cost-effectiveness of tezepelumab in Canada for severe asthma. J. Med. Econ., 2023, 26(1), 902-914.
[http://dx.doi.org/10.1080/13696998.2023.2234235] [PMID: 37417781]

Chagas, G.C.L.; Xavier, D.; Gomes, L.; Ferri-Guerra, J.; Oquet, R.E.H. Effects of tezepelumab on quality of life of patients with moderate-to-severe, uncontrolled asthma: Systematic review and meta-analysis. Curr. Allergy Asthma Rep., 2023, 23(6), 287-298.
[http://dx.doi.org/10.1007/s11882-023-01085-y] [PMID: 37191902]

Study to evaluate efficacy and safety of tezepelumab in reducing oral corticosteroid use in adult patients with severe Asthma (WAYFINDER). Patent NCT05274815, 2023.

Wechsler, M.E.; Menzies-Gow, A.; Brightling, C.E.; Martin, N.; Cook, B.; Kabelis, P. SUNRISE: A phase 3, parallel-group study to evaluate the efficacy and safety of tezepelumab in reducing OCS use in OCS-dependent patients with severe asthma. In: A31 GLOBAL AND ENVIRONMENTAL INFLUENCES IN ASTHMA; American Thoracic Society, 2023; pp. A1295-A1295.
[http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A1295]

Study to evaluate the pharmacokinetics of tezepelumab in children with asthma (TRAILHEAD) Patent NCT04673630, 2022.

REVErsing airway remodelling with tezepelumab (REVERT). Patent NCT05651841, 2023.

Tezepelumab COPD exacerbation study (COURSE). Patent NCT04039113, 2023.

Efficacy and safety of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT). Patent NCT04851964, 2023.

Rind, D.M.; McQueen, R.B.; Herron-Smith, S.; Herce-Hagiwara, B.; Gutierrez, E.; Campbell, J.D.; Fluetsch, N.; Pearson, S.D. The effectiveness and value of tezepelumab for severe asthma. J. Manag. Care Spec. Pharm., 2022, 28(5), 577-580.
[http://dx.doi.org/10.18553/jmcp.2022.28.5.577] [PMID: 35471071]

Williams, D.M. The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma. J. Manag. Care Spec. Pharm., 2022, 28(5), 581-583.
[http://dx.doi.org/10.18553/jmcp.2022.28.5.581] [PMID: 35471066]